

PB2199 A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Topic: 22. Stem cell transplantation - Clinical

Jie Xu¹, Fansheng Kong¹, Siyuan Cui¹, Kui Liu¹, Zhaoxia Liu¹, Jingyi Wang¹, Wei Zheng¹, Yanfeng Zhou¹, Ruirong Xu¹

¹ Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China

Background: The data of PEG-rhG-CSF on hematopoietic recovery after allogeneic hematopoietic stem cell transplantation is few in China.

Aims: To observe the efficacy and safety of PEG-rhG-CSF on hematopoietic recovery after allogeneic hematopoietic stem cell transplantation in the real world study.

Methods: 103 patients after allo-HSCT were enrolled in this study from January 2019 to October 2021. PEG-rhG-CSF(xinruibai) was used in the hematopoietic recovery and given in the dose of 100µg/kg on day +1 and day +8. Hematopoietic stem cell implantation time and recovery of white blood cells (WBC) and platelet (PLT) implantable syndrome and infectious fever were observed until day +60. The patients were divided into Aplastic Anemia group and hematological malignancy group for further study.

Results: All patients got neutrophil implantation successfully and the median neutrophil implantation time was 12 (7-25) d. 3 patients were failed to complete platelet implantation and the platelet implantation rate is 97%. The median platelet implantation time of the other 101 evaluable patients was 17 (10-47) d. The incidence of implantable syndrome and infection was low and there was no related death case. There were no significant differences of the neutrophil implantation time 11.5 (7-25) d vs 12 (9-23) d ($P=0.05$) and platelet implantation time 17.5 (10-43) d vs 17 (11-47) d ($P=0.05$) between Aplastic Anemia and hematological malignancy groups respectively. There was no significant difference in the incidence of fever and duration of fever between two groups ($P=0.05$).

Summary/Conclusion: The efficacy of PEG-rhG-CSF in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation is good, without severe untoward effects. There is no obvious difference in hematopoietic recovery in Aplastic Anemia and hematological malignancy.

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at <https://journals.lww.com/hemasphere/pages/default.aspx>.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.